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OBJECTIVE—Circulating glucose inhibits glucose production
in normal rodents and humans, but this glucose effectiveness is
disrupted in diabetes due partly to sustained hyperglycemia. We
hypothesize that hyperglycemia in diabetes impairs hypothalamic
glucose sensing to lower glucose production, and changes of
glucose transporter-1 (GLUT1) in the hypothalamic glial cells are
responsible for the deleterious effects of hyperglycemia in vivo.
RESEARCH DESIGN AND METHODS—We tested hypotha-
lamic glucose effectiveness to increase hypothalamic glucose
concentration and lower glucose production in rats induced with
streptozotocin (STZ) uncontrolled diabetes, STZ and phlorizin,
and whole-body and hypothalamic sustained hyperglycemia. We
next assessed the content of glial GLUT1 in the hypothalamus,
generated an adenovirus expressing GLUT1 driven by a glial
ﬁbrillary acidic protein (GFAP) promoter (Ad-GFAP-GLUT1), and
injected Ad-GFAP-GLUT1 into the hypothalamus of rats induced
with hyperglycemia. Pancreatic euglycemic clamp and tracer-
dilution methodologies were used to assess changes in glucose
kinetics in vivo.
RESULTS—Sustained hyperglycemia, as seen in the early onset
of STZ-induced diabetes, disrupted hypothalamic glucose sensing
to increase hypothalamic glucose concentration and lower glucose
production in association with reduced GLUT1 levels in the
hypothalamic glial cells of rats in vivo. Overexpression of hypotha-
lamic glial GLUT1 in STZ-induced rats with reduced GLUT1 acutely
normalized plasma glucose levels and in rats with selectively in-
duced hypothalamic hyperglycemia restored hypothalamic glucose
effectiveness.
CONCLUSIONS—Sustained hyperglycemia impairs hypothalamic
glucose sensing to lower glucose production through changes in
hypothalamic glial GLUT1, and these data highlight the critical role
of hypothalamic glial GLUT1 in mediating glucose sensing to
regulate glucose production. Diabetes 60:1901–1906, 2011
S
ustained hyperglycemia per se disrupts glucose
homeostasis (1). When hyperglycemia is normal-
ized in diabetic rodents (2–4) and humans (5),
insulin action, b-cell insulin secretion, and he-
patic glucose production regulation are restored in di-
abetes. With respect to glucose production regulation, an
increase in circulating glucose levels inhibits glucose
production in normal rodents (6) and humans (5,7,8)
independent of changes in plasma insulin levels. This
glucose effectiveness in lowering glucose production is
completely disrupted in diabetic rodents (6) and humans
(7). Importantly, normalization of plasma glucose levels
in diabetic rodents with an oral inhibitor of the sodium-
dependent glucose transporter (4) and in diabetic humans
with a 3-day insulin treatment (5) rescues glucose effec-
tiveness to lower glucose production.
To date, the mechanisms responsible for the deleterious
effect of sustained hyperglycemia on glucose production
regulation remain unclear. In light of recent discoveries
that the central nervous system (CNS) (9,10), in particular
hypothalamic glucose sensing (11), lowers glucose pro-
duction in rodents, we here investigated whether sustained
hyperglycemia impairs CNS glucose sensing to regulate
glucose production and whether changes of glucose
transporter-1 (GLUT1) in the hypothalamic glial cells are
responsible for the deleterious metabolic effects of sus-
tained hyperglycemia in vivo (Fig. 1A).
RESEARCH DESIGN AND METHODS
Animal preparation. SD male rats aged 8 weeks weighing 250–300 g were
studied. Rats were subjected to a standard light-dark cycle and were main-
tained on a regular chow and had ad libitum access to distilled water. In-
dwelling catheters were placed in the right internal jugular vein and left
carotid artery for infusion and sampling purposes. Rats were implanted with
bilateral intrahypothalamic catheters placed within the mediobasal hypothal-
amus (MBH) as previously described (12,13). The coordinates used were 3.1
mm posterior from bregma, 0.4 mm lateral of midline, and 9.6 mm below skull
surface. Recovery between surgical procedures was monitored by measuring
daily food intake and body weight gain. To ensure comparable postabsorptive
nutritional status, rats were limited to 20 g of food the day before experi-
mentation. All study protocols were approved by the Institutional Animal Care
and Use Committee of University Health Network.
Pancreatic (basal insulin) euglycemic clamps. An infusion of intra-
hypothalamic vehicle (0.9% wt/vol NaCl) or 2 mmol/L glucose was maintained
throughout the experiments. A primed-continuous infusion of [3-
3H]glucose
(Perkin Elmer; 40 mCi bolus; 0.4 mCi/min thereafter) was initiated at 0 min and
maintained through the study to assess glucose kinetics via the use of the
tracer-dilution methodology. After a basal period of 90 min, a basal pancreatic
insulin clamp was performed for the ﬁnal 2 h (90–210 min) of the study;
a continuous coinfusion of insulin (0.8 mU/kg/min) along with somatostatin
(3 mg/kg/min) was administered, and a variable infusion of 25% glucose solu-
tion was administered as needed to clamp and maintain the plasma glucose
concentration at levels similar to the basal state. Plasma samples were collected
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BRIEF REPORTevery 10 min for determination of [3-
3H]glucose speciﬁca c t i v i t ya sw e l la s
hormone levels.
Hypothalamic glucose level measurements. MBH (10–12 mg) tissues were
harvested at the end of the clamp studies and frozen in liquid nitrogen. MBH
tissues were subsequently weighed and homogenized in buffer to a ﬁnal vol-
ume of 15 mL (2 mmol/L Tris-HCl and 1 mmol/L EDTA, pH 7) as previously
described (14). The homogenate (10 mL) was pipetted into an Analox Glucose
Analyzer (Analox, London, U.K.), and glucose concentration in the homoge-
nate was determined based on a glucose oxidase method. Readings in
micromoles per liter obtained from the glucose analyzer were then converted
to micromoles per gram of tissue based on the total volume of homogenate
and the corresponding tissue weight (early-onset uncontrolled diabetic mode
[with or without phlorizin]; whole-body and hypothalamic sustained hyper-
glycemic models; and construction of glial-speciﬁc adenoviruses, cell culture,
and in vitro cell infection; see Supplementary Data).
Adenovirus-expressing rats with uncontrolled diabetes. Rats received
6 mL( 3mL per side) of puriﬁed glial-speciﬁc adenovirus (GLUT1-expressing
Ad-GFAP-GLUT1 or control Ad-GFAP-LacZ) via the intrahypothalamic cannula
at the time of the surgery. Tissue harvesting after 4 days revealed an over-
expression of the adenovirus selectively in MBH glial cells (Fig. 3). A group of
rats were administered intravenous streptozotocin (STZ) (60 mg/kg) at the time
of vascular catheterization 2 days after administration of intrahypothalamic Ad-
GFAP-LacZ or Ad-GFAP-GLUT1. Rats received an additional dose of STZ 20 h
after the initial dose to ensure rapid development of uncontrolled diabetes.
Adenovirus-expressing rats with hypothalamic hyperglycemia. One day
before the start of the 24-h infusion of 4 mmol/L glucose, Ad-GFAP-LacZ or
Ad-GFAP-GLUT1 was injected 3 mL per side via the intrahypothalamic can-
nula. The 24-h intrahypothalamic infusion and the clamp studies were sub-
sequently conducted as described in Supplementary Methods.
Immunoﬂuorescence. Whole rat brains were ﬁxed via transcardial perfusion
with PBS and then 4% PFA, and brain sections containing the MBH were placed
inOCT-ﬁlleddisposablebasemoldsandfrozen.Withtheuseofacryostat(Leica
CM1950), frozen sections were cut at a thickness of 10 mm. The slides were
permeabilized for 10 min with 0.5% Tween, followed by 13 PBS washes. Slides
underwent blocking for 1 h with 10% goat serum. Primary antibodies (over-
night 4°C) used were chicken anti-bb –galactosidase (LacZ) from Abcam
(1:100), mouse anti-GFAP from Sigma (1:200 for LacZ + GFAP costaining,
1:300 for GLUT1 + GFAP costaining), rabbit anti-GLUT1 from Alpha Di-
agnostic (1:100), and mouse anti-NeuN from Chemicon (1:400). Secondary
antibodies (1 h) used were Alexa Fluor 488 anti-mouse (1:500), Alexa Fluor
546 anti-rabbit (1:500), and Alexa Fluor 546 anti-chicken (1:1,000). The slides
were read with an Olympus ﬂuorescence microscope.
FIG. 1. STZ-induced hyperglycemia reduces glial GLUT1 in the hypothalamus and inhibits CNS glucose effectiveness to elevate hypothalamic
glucose concentration and lower glucose production. A: Schematic representation of the working hypothesis. Sustained hyperglycemia in diabetes
disrupts hypothalamic glucose sensing to increase hypothalamic glucose concentration and lower GP through a reduction of hypothalamic glial
GLUT1. B: Experimental protocol. C: GP. *P < 0.0001 vs. other clamp groups. D: Hypothalamic glucose concentration. *P < 0.001 vs. other groups.
E: Continuous infusion of intravenous phlorizin rapidly normalized and maintained plasma glucose. **P < 0.01; ***P < 0.001 vs. control.
F: Pancreatic clamp protocol modiﬁed to include the concurrent infusion of phlorizin or vehicle (VEH). G: GP. *P < 0.01 vs. intrahypothalamic
saline-infused STZ + phlorizin rats. H: Percent suppression of glucose production from basal. *P < 0.05 vs. other groups. I: Hypothalamic glucose
concentration. *P < 0.05 vs. other groups. J: Expression of GLUT1 and GLUT3 proteins in wedges of the MBH was assessed via immunoblotting and
quantiﬁed using densitometry. *P < 0.05 vs. other groups. GP, glucose production; i.h., intrahypothalamic; i.v., intravenous; PG, plasma glucose.
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glucose oxidase method, using an Analox Glucose Analyzer (Analox, London,
U.K.). Plasma glucose tracer ([3-
3H]glucose) speciﬁc activity was determined
in deproteinized plasma samples with a scintillation counter (Beckman
Coulter LS6500), and [3-
3H]glucose measurements were used to determine the
rates of glucose kinetics using steady state formulas. Radioimmunoassays
(RIA) were used to determine the plasma concentrations of insulin and glu-
cagon (kits RI-13 K and GL-32K; Linco Research, St. Charles, MO).
Calculations. Statistical analysis was done by two-way ANOVA to compare
across the groups, followed by a Tukey post hoc test to compare between
groups. Data are presented as means 6 SEM. The presented basal values for
glucose concentration and rates of glucose ﬂuxes are averages for times 60–90
min, whereas those for the clamp period are the averages for the ﬁnal 30 min
(180–210 min) of the procedure.
RESULTS
Sustained hyperglycemia in uncontrolled diabetes re-
duces hypothalamic glucose sensing and glial GLUT1.
In the presence of hypoinsulinemia and basal glucagon
levels (Supplementary Fig. 1), basal glucose production
was signiﬁcantly (P , 0.001) elevated in STZ-induced di-
abetic rats receiving intrahypothalamic saline versus
normal rats (Fig. 1B and C). During the clamps, intra-
hypothalamic glucose (2 mmol/L) failed to lower glucose
production (Fig. 1C) and increase hypothalamic glucose
concentration (Fig. 1D) in STZ-induced diabetic rats
as compared with intrahypothalamic glucose in normal
rats, which was effective in lowering glucose production
(Fig. 1C) and increasing hypothalamic glucose concen-
tration (Fig. 1D). Glucose uptake was comparable within
groups (Supplementary Fig. 2).
We normalized glucose in diabetes and evaluated CNS
glucose effectiveness. We infused intravenous phlorizin to
normalize glucose in STZ-injected rats for 24 h (Fig. 1E),
and during the clamps intrahypothalamic glucose lowered
glucose production (Fig. 1G and H). Importantly, the abil-
ity of intrahypothalamic glucose to elevate hypothalamic
glucose concentration was restored in STZ-induced diabetic
rats that received phlorizin (Fig. 1I). Thus lowering of glucose
levels per se in diabetes restores CNS glucose effectiveness.
MBH wedges were obtained from the STZ-induced di-
abetic rats, and the protein levels of glial GLUT1 (45 kDa)
were signiﬁcantly reduced compared with normal (Fig. 1J).
A nonsigniﬁcant trend toward reduction of the neuronal
GLUT3 (Fig. 1J; 27.6 6 7.3% reduction from control; P =
0.11) and the more heavily glycosylated BBB endothelial
isoforms of GLUT1 (55 kDa; Fig. 1J;1 8 . 56 10.8% re-
duction [doublet pooled in measurement] from control;
P = 0.45) was observed. The signiﬁcant reduction of hy-
pothalamic glial GLUT1 in STZ-induced diabetic rats was
reversed when hyperglycemia per se is normalized in STZ-
induced rats that received intravenous phlorizin infusion
(Fig. 1J). Thus hyperglycemia disrupts CNS glucose ef-
fectiveness in association with a reduction in hypothalamic
glial GLUT1.
Whole body or hypothalamic hyperglycemia impairs
hypothalamic glucose sensing. We infused intravenous
glucose into normal rats and mimicked the hyperglycemic
insult in uncontrolled diabetes (Fig. 2A). Before the
clamps, the glucose infusion was stopped and the plasma
glucose levels were normalized in 1–1.5 h. Glucose in-
trahypothalamic failed to lower glucose production
(Fig. 2B) and increase hypothalamic glucose concentration
(Fig. 2C) in 24-h intravenous glucose-infused rats. Another
FIG. 2. Whole-body and hypothalamic sustained hyperglycemia impair CNS glucose effectiveness to increase hypothalamic glucose concentration
and lower glucose production. A: Plasma glucose levels before clamp studies after the 24-h intravenous infusion period (whole-body glucotoxicity).
*P < 0.01 vs. control. B: Glucose production. C: Hypothalamic glucose concentration. D: Glucose production. *P < 0.0001 vs. other groups.
E: Hypothalamic glucose concentration. *P < 0.05 vs. other groups. F: Glucose production. G: Hypothalamic glucose concentration. i.h., intra-
hypothalamic; i.v., intravenous.
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glucose for 24 h to induce hypothalamic hyperglycemia. To
select the glucose concentration to be used, we ﬁrst per-
formed dose-response clamps for intrahypothalamic glu-
cose. Intrahypothalamic glucose (4 mM) for 210 min was
unable to increase hypothalamic glucose concentration and
lower glucose production as compared with 2 mmol/L
intrahypothalamic glucose (Fig. 1B–D and Fig. 2D and E).
This inability of intrahypothalamic glucose (4 mmol/L) to
increase hypothalamic glucose concentration was also seen
in rats with either diabetes or whole-body hyperglycemia
when intrahypothalamic glucose (2 mmol/L) was adminis-
tered (Fig. 1D and Fig. 2C). Consequently, we determined to
infuse glucose intrahypothalamically at 4 mmol/L to induce
hypothalamic hyperglycemia.
Although the 24-h intrahypothalamic glucose (4 mmol/L)-
infused rats did not display elevated plasma glucose levels,
the intrahypothalamic glucose (4 mmol/L) infusion was still
terminated 1.5 h before the start of the clamps to keep
consistent with 24-h intravenous glucose infused rats. This
24-h hypothalamic glucose challenge negated the ability
of intrahypothalamic glucose to lower glucose production
(Fig. 2F) and increase hypothalamic glucose concentration
(Fig. 2G). Thus an induction of whole-body or hypothalamic
hyperglycemia impairs CNS glucose effectiveness.
Overexpressing hypothalamic glial GLUT1 in vitro
and in vivo. GLUT1 in the MBH glial cells regulates glucose
uptake from the extracellular to the intracellular compart-
ment. If glucotoxicity disrupts CNS glucose sensing via
a reduction in hypothalamic glial GLUT1 and consequently
hypothalamic intracellular glucose concentration, then res-
cuing the reduction of hypothalamic glial GLUT1 in rats
with sustained hyperglycemia could restore CNS glucose
effectiveness. We generated an adenovirus expressing
FIG. 3. Overexpressing glial GLUT1 in the hypothalamus of STZ-induced rats acutely normalizes plasma glucose levels. A: C6 (glial) and PC12
(neuronal) cells were transduced with adenovirus expressing GLUT1 with a GFAP promoter (Ad-GFAP-GLUT1). GLUT1 expression was measured
48-h post-transduction via immunoblotting. Signiﬁcant GLUT1 overexpression was detected in C6 (*P < 0.05) but not in PC12 cells relative to
control cell (CON). B: Hypothalamic tissues were obtained from rats injected with adenovirus expressing LacZ with a GFAP promoter (Ad-GFAP-
LacZ) or Ad-GFAP-GLUT1 for 4 days. GLUT1 expression showed a 3.5-fold increase in GLUT1 expression in rat brains injected with GLUT1 (n =4 )
adenovirus vs. LacZ (n = 4) adenoviral injection. *P < 0.05. C: Rat hypothalamic frozen sections obtained 4 days after the injection of Ad-GFAP-GLUT1.
Sections were stained with anti-GLUT1, anti-GFAP, and anti-NeuN antibodies. Coimmunostaining indicated that the GLUT1 signals colocalized with
GFAP, but not NeuN staining, in the arcuate nucleus (ARC). D: Plasma glucose levels in STZ-injected rats harboring Ad-GFAP-LacZ or Ad-GFAP-
GLUT1. *P < 0.01 vs. MBH control Ad-GFAP-LacZ–injected rats. (A high-quality color representation of this ﬁgure is available in the online issue.)
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promoter (Ad-GFAP-LacZ). Transduction of Ad-GFAP-
LacZ in C6 glial cells, but not PC12 neuronal cells, revealed
strong b-galactosidase staining (Supplementary Fig. 3A).
Direct injection of Ad-GFAP-LacZ into the MBH expressed
LacZ in GFAP-expression cells in the arcuate nucleus
in vivo (Supplementary Fig. 3B). GFAP was colocalized
with 98.8 + 1.2% of LacZ (n = 4). We then constructed
an adenovirus expressing GLUT1 driven by GFAP (Ad-
GFAP-GLUT1). Transduction of Ad-GFAP-GLUT1 in C6
signiﬁcantly increased glial isoforms of GLUT1 (Fig. 3A),
whereas Ad-GFAP-GLUT1 had no effects in PC12 (Fig.
3A). Injection of Ad-GFAP-GLUT1 into the MBH increased
glial GLUT1 (Fig. 3B), which were colocalized with GFAP
(95.9 + 1.1% of GLUT1 [n = 5]), but not NeuN (Fig. 3C). We
developed a molecular approach to increase GLUT1 in the
hypothalamic glial cells in vivo.
Overexpressing hypothalamic glial GLUT1 in rats
induced with uncontrolled diabetes and hypothalamic
hyperglycemia.Toevaluatewhetheroverexpressinghypo-
thalamic glial GLUT1 in STZ-induced diabetic rats with
reduced hypothalamic glial GLUT1 (Fig. 1J) could rescue
MBH glucose sensing, we injected MBH Ad-GFAP-GLUT1
or Ad-GFAP-LacZ into STZ-injected rats. Plasma glucose
levels were elevated to ;280 mg/dL in rats that received
Ad-GFAP-LacZ and a 21.5 h-prior STZ injection (Fig. 3D).
In contrast, plasma glucose levels were normalized in rats
with Ad-GFAP-GLUT1 who underwent the same STZ in-
jection protocol (Fig. 3D).
Next, we injected Ad-GFAP-GLUT1 or LacZ into MBH of
rats with hypothalamic hyperglycemia (Fig. 4A and Fig. 2F
and G). The ability of intrahypothalamic glucose to in-
crease hypothalamic glucose concentration was restored
in hypothalamic hyperglycemic rats when injected with
hypothalamic Ad-GFAP-GLUT1 (Fig. 4B), suggesting that
overexpressing MBH glial GLUT1 resuscitates the elevation
of hypothalamic glucose concentration in the intracel-
lular compartment. This restoration of elevated hypo-
thalamic glucose concentration rescued the ability of
intrahypothalamic glucose (MBH glucose sensing) to lower
glucose production in hypothalamic hyperglycemic rats
(Fig. 4C). Of note, hypothalamic glucose concentration
(0.34
+/2 0.07 mmol/g) and glucose production during the
clamps (9.2
+/2 0.6 mg $ kg
21 $ min
21)w e r en o ta l t e r e di n
hypothalamic hypergylycemic rats injected with MBH
Ad-GFAP-GLUT1 and that underwent intrahypothalamic
saline clamp studies (n = 4). This suggests that changes in
MBH glial GLUT1 mediate MBH glucose sensing (but not
under saline-infused condition) to regulate hypothalamic
glucose concentration and glucose production. Together,
overexpressing hypothalamic glial GLUT1 in two independent
hyperglycemic models restores CNS glucose effectiveness.
DISCUSSION
The underlying mechanisms responsible for the deleteri-
ous effects of sustained hyperglycemia on glucose ho-
meostasis remain unclear in both rodents and humans. The
current set of data demonstrated sustained hyperglycemia
as seen in uncontrolled diabetes impairs CNS glucose ef-
fectiveness to increase hypothalamic glucose concentra-
tion and lower glucose production through changes in
hypothalamic glial GLUT1.
GLUT1 facilitates glucose uptake into the intracellular
compartment for subsequent metabolism (15,16). Consis-
tent with the working hypothesis that a reduction of
hypothalamic glial GLUT1 is responsible for the metabolic
impairments induced by hyperglycemia, hyperglycemia
suppresses BBB glucose transport in STZ-induced rodents
(17,18), although glucose uptake into the glial cells was
not determined. In addition, hyperglycemia in maternal
diabetes suppresses GLUT1 and glucose transport in
preimplantation embryos (19) and may lead to diabetic
embryopathy (20). In parallel, Alzheimer disease and neu-
rodegeneration are caused by impaired glucose uptake and
metabolism as well as hyperphosphorylation of t in the
brain (21,22). A reduction in brain GLUT1 is associated with
these defects in a human brain with Alzheimer disease (23).
Together, the ability of GLUT1 to facilitate intracellular
glucose uptake and regulate glucose metabolism plays an
important role in certain disease progression, and changes
in hypothalamic glial GLUT1, as suggested by the current
study, alter peripheral glucose regulation in diabetes.
A surprising aspect of our ﬁndings is that in all three
hyperglycemic models, hypothalamic glucose concentra-
tion was not elevated after either MBH saline or 2 mmol/L
glucose (glucose-sensing) clamps. These data indicate
a potential MBH intracellular adaptive response to hyper-
glycemia. In light of the fact that MBH glial GLUT1 was
reduced in uncontrolled diabetes (Fig. 1J) and that hyper-
glycemia suppresses GLUT1 (supported by the current
phlorizin study as well as the studies described above), it is
reasonable to postulate that the lack of increase in MBH
FIG. 4. Overexpressing hypothalamic glial GLUT1 in the hypothalamic hyperglycemic rats rescues CNS glucose sensing. A: Experimental protocol.
B: Hypothalamic glucose concentration. *P < 0.05 vs. other groups. C: Glucose production. *P < 0.05 vs. other groups. i.h., intrahypothalamic.
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models represents a lack of elevation of intracellular MBH
glucose concentration. In fact, when the hypothalamic
hyperglycemic rats were injected with MBH Ad-GFAP-
GLUT1, the ability of MBH glucose sensing to elevate MBH
glucose concentration was restored. Future experiments
aimed to clarify the ability of hyperglycemia to alter
GLUT1 protein expression and glucose uptake in a glial
cell culture model will strengthen this working hypothesis.
Another important unanswered question in our study is
how restoration of hypothalamic glucose elevation in-
duced by CNS glucose sensing lowers glucose production
in hyperglycemic models. We put forward a working hy-
pothesis that in diabetes overexpressing hypothalamic
glial GLUT1 enhances glucose uptake into glial cells and
elevates intracellular glucose and lactate concentration in
response to CNS glucose sensing. Lactate will be shuttled
into neurons to trigger downstream biochemical/signaling
pathways leading to the inhibition of glucose production.
Consistent with this hypothesis, MBH lactate infusion
lowers glucose production in uncontrolled diabetes (24).
Since glucose sensing in POMC neurons regulates peripheral
glucose homeostasis in rodents (25), it would be necessary
also to evaluate whether the restoration of hypothalamic
glucose elevation (or indirectly via lactate) triggers signaling
events within MBH POMC neurons to lower glucose pro-
duction in our current hyperglycemic models.
In summary, our data highlight the critical role of hypo-
thalamic glial GLUT1 in mediating hypothalamic glucose
sensing to regulate glucose production in vivo.
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